nevirapine has been researched along with Lipodystrophy in 25 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Lipodystrophy: A collection of heterogenous conditions resulting from defective LIPID METABOLISM and characterized by ADIPOSE TISSUE atrophy. Often there is redistribution of body fat resulting in peripheral fat wasting and central adiposity. They include generalized, localized, congenital, and acquired lipodystrophy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the virologic, immunologic, and clinical benefit of switching the PI to nevirapine in patients with HIV-associated lipodystrophy and sustained viral suppression before entry in the study." | 9.09 | Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. ( Balagué, M; Bonjoch, A; Clotet, B; Domingo, P; Francia, E; Fumaz, CR; Gel, S; Johnston, S; Lange, J; Negredo, E; Paredes, R; Romeu, J; Ruiz, L, 2001) |
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 7.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| "This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment." | 7.76 | Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010) |
| "In the CHAPAS-3 trial, HIV-infected children (ART-naive or on d4T for ≥2 years without clinical lipodystrophy) were randomized to d4T, abacavir or zidovudine with lamivudine (3TC) plus a non-nucleoside reverse transcriptase inhibitor." | 5.19 | Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. ( Abongomera, G; Arach, B; Asiimwe, AR; Cook, A; Gibb, DM; Kabamba, D; Kayiwa, J; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; Komunyena, J; Mirembe, G; Mulenga, V; Musiime, V; Nansubuga, C; Walker, SA; Wavamunno, P; Zangata, D, 2014) |
| "To assess the virologic, immunologic, and clinical benefit of switching the PI to nevirapine in patients with HIV-associated lipodystrophy and sustained viral suppression before entry in the study." | 5.09 | Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. ( Balagué, M; Bonjoch, A; Clotet, B; Domingo, P; Francia, E; Fumaz, CR; Gel, S; Johnston, S; Lange, J; Negredo, E; Paredes, R; Romeu, J; Ruiz, L, 2001) |
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 3.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| "This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment." | 3.76 | Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010) |
| "PI substitution with nevirapine improved lipid profile in our patients, although this strategy did not show significant changes in body fat or lipodystrophy." | 3.74 | Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. ( Amador, JT; Conejo, PR; Fontelos, PM; Gomez, ML; Gonzalez-Tome, MI; Peña, MJ, 2008) |
| "Lipodystrophy was evaluated by clinical examination and morphological measurements." | 2.71 | Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. ( Crespo, M; Ferrer, E; Fisac, C; Fumero, E; Gatell, JM; Podzamczer, D; Ribera, E; Roson, B; Virgili, N, 2005) |
| " Pressure of work and insufficient perceived benefit of side-effect recording are suspected causes." | 1.37 | Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi. ( Lungu, M; Mathews, T; Tapsfield, J; van Oosterhout, JJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tapsfield, J | 1 |
| Mathews, T | 1 |
| Lungu, M | 1 |
| van Oosterhout, JJ | 1 |
| Musiime, V | 1 |
| Cook, A | 1 |
| Kayiwa, J | 1 |
| Zangata, D | 1 |
| Nansubuga, C | 1 |
| Arach, B | 1 |
| Kenny, J | 1 |
| Wavamunno, P | 1 |
| Komunyena, J | 1 |
| Kabamba, D | 1 |
| Asiimwe, AR | 1 |
| Mirembe, G | 1 |
| Abongomera, G | 1 |
| Mulenga, V | 1 |
| Kekitiinwa, A | 1 |
| Kityo, C | 1 |
| Walker, SA | 1 |
| Klein, N | 1 |
| Gibb, DM | 1 |
| Tsuchiya, N | 1 |
| Pathipvanich, P | 1 |
| Wichukchinda, N | 1 |
| Rojanawiwat, A | 1 |
| Auwanit, W | 1 |
| Ariyoshi, K | 1 |
| Sawanpanyalert, P | 1 |
| Gleason, RL | 1 |
| Caulk, AW | 1 |
| Seifu, D | 1 |
| Parker, I | 1 |
| Vidakovic, B | 1 |
| Getenet, H | 1 |
| Assefa, G | 1 |
| Amogne, W | 1 |
| Birbal, S | 1 |
| Dheda, M | 1 |
| Ojewole, E | 1 |
| Oosthuizen, F | 1 |
| Gonzalez-Tome, MI | 1 |
| Amador, JT | 1 |
| Peña, MJ | 1 |
| Gomez, ML | 1 |
| Conejo, PR | 1 |
| Fontelos, PM | 1 |
| Cournil, A | 1 |
| Coudray, M | 1 |
| Kouanfack, C | 1 |
| Essomba, CN | 1 |
| Tonfack, CA | 1 |
| Biwolé-Sida, M | 1 |
| Delaporte, E | 1 |
| Bork, K | 1 |
| Laurent, C | 1 |
| Guaraldi, G | 1 |
| Zona, S | 1 |
| Orlando, G | 1 |
| Carli, F | 1 |
| Stentarelli, C | 1 |
| Luzi, K | 1 |
| Garlassi, E | 1 |
| Menozzi, M | 1 |
| Bagni, P | 1 |
| Adorni, F | 1 |
| Negredo, E | 2 |
| Ribalta, J | 1 |
| Paredes, R | 2 |
| Ferré, R | 1 |
| Sirera, G | 1 |
| Ruiz, L | 2 |
| Salazar, J | 1 |
| Reiss, P | 1 |
| Masana, L | 1 |
| Clotet, B | 2 |
| Sullivan, JR | 1 |
| Rachlis, A | 1 |
| Phillips, E | 1 |
| Leen, CL | 1 |
| Fisac, C | 1 |
| Fumero, E | 1 |
| Crespo, M | 1 |
| Roson, B | 1 |
| Ferrer, E | 1 |
| Virgili, N | 1 |
| Ribera, E | 1 |
| Gatell, JM | 2 |
| Podzamczer, D | 1 |
| Abbas, I | 1 |
| Rovira, J | 1 |
| Casanovas, J | 1 |
| Aurpibul, L | 1 |
| Puthanakit, T | 1 |
| Lee, B | 1 |
| Mangklabruks, A | 1 |
| Sirisanthana, T | 1 |
| Sirisanthana, V | 1 |
| Dieleman, JP | 1 |
| Hillebrand-Haverkort, ME | 1 |
| van der Ende, ME | 1 |
| Sturkenboom, MC | 1 |
| Lange, JM | 1 |
| Stricker, BH | 1 |
| Aldeen, T | 1 |
| Wells, C | 1 |
| Hay, P | 1 |
| Davidson, F | 1 |
| Lau, R | 1 |
| Martínez, E | 1 |
| Barreiro, P | 1 |
| Soriano, V | 1 |
| Blanco, F | 1 |
| Casimiro, C | 1 |
| de la Cruz, JJ | 1 |
| González-Lahoz, J | 1 |
| Moyle, G | 1 |
| Baldwin, C | 1 |
| Fornataro, K | 1 |
| Domingo, P | 2 |
| Francia, E | 1 |
| Balagué, M | 1 |
| Gel, S | 1 |
| Bonjoch, A | 1 |
| Fumaz, CR | 1 |
| Johnston, S | 1 |
| Romeu, J | 1 |
| Lange, J | 1 |
| Carr, A | 1 |
| Hudson, J | 1 |
| Chuah, J | 1 |
| Mallal, S | 1 |
| Law, M | 1 |
| Hoy, J | 1 |
| Doong, N | 1 |
| French, M | 1 |
| Smith, D | 1 |
| Cooper, DA | 1 |
| Matías-Guiu, X | 1 |
| Pujol, RM | 1 |
| Domingo, JC | 1 |
| Arroyo, JA | 1 |
| Sambeat, MA | 1 |
| Vázquez, G | 1 |
1 review available for nevirapine and Lipodystrophy
| Article | Year |
|---|---|
Perspectives on HAART: switch maintenance therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV | 2003 |
8 trials available for nevirapine and Lipodystrophy
| Article | Year |
|---|---|
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Topics: Anthropometry; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Dideoxynucleosides | 2014 |
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
Topics: Adult; Anti-HIV Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; HIV Infections; HIV | 2002 |
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2005 |
Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV | 2000 |
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Topics: Adult; Anthropometry; Anti-HIV Agents; Body Composition; CD4 Lymphocyte Count; Cholesterol; Drug The | 2001 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideox | 2001 |
Switching to nevirapine--results after one year.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Fema | 2001 |
Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy.
Topics: Adipocytes; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Blood Glucose; | 2001 |
16 other studies available for nevirapine and Lipodystrophy
| Article | Year |
|---|---|
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care Facilities; Anti-HIV Agents; Cross-S | 2011 |
Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.
Topics: Adult; Aged; Anti-Retroviral Agents; Asia; CD4 Lymphocyte Count; Cohort Studies; Drug Administration | 2014 |
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reacti | 2015 |
Adverse drug reactions associated with antiretroviral therapy in South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Exanthema; Fema | 2016 |
Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Antiretroviral Therapy, Highly Active; CD4 Lymph | 2008 |
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV; HIV In | 2010 |
Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Fat Dist | 2011 |
'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effects.
Topics: Anti-HIV Agents; Dermatitis, Irritant; Diagnosis, Differential; Drug Eruptions; HIV Infections; Huma | 2003 |
Validation by simulation of a clinical trial model using the standardized mean and variance criteria.
Topics: Anti-Retroviral Agents; Calibration; Cholesterol; Clinical Trials as Topic; Computer Simulation; Dat | 2006 |
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; C | 2007 |
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
Topics: Adult; Cardiovascular Diseases; CD4 Lymphocyte Count; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 1998 |
Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lipodystrophy; Ma | 1999 |
[Lipodystrophy and antiretroviral agents].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Prote | 1999 |
Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution.
Topics: Acquired Immunodeficiency Syndrome; Adipose Tissue; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynuc | 2000 |
Switching drugs for lipodystophy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Administration Schedule; HI | 1999 |
[Delayed virus suppression has its price. Heart and liver are no longer secondary theaters].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical | 2002 |